Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
The Effect of Inhaled Nitric Oxide on Pulmonary Gas-exchange in COPD
NCT04231760Phase 2Not yet recruiting
- Sponsor
- University of Alberta
- Start
- Dec 2026
- Primary completion
- Dec 2027
- Modality
- DNA Intercalators/Alkylators, Inhalation Devices
01
Overview
Phase 2, randomised, double-blind trial of nitric oxide in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by University of Alberta. Primary endpoint: Ventilation-perfusion matching (log SDQ). Planned start Dec 2026; status: not yet recruiting.
02
Drugs
nitric oxide
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT04231760.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04231760.